Prometheus Biosciences, Inc. - Common Stock (NQ:RXDX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 15, 2023 Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	199.92 (9)
Ask (Size)	199.99 (7)
Prev. Close	199.92
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	47,809,476
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Shares of Exscientia Jumped on Wednesday ↗

July 12, 2023

The company may be riding the wave of an AI healthcare boom.

Via The Motley Fool

From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs ↗

July 07, 2023

Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as...

Via Benzinga

Performance

More News

Why Shares of Ventyx Biosciences Rose Monday ↗

July 03, 2023

Via The Motley Fool

Is Merck Stock a Top Buy Right Now? ↗

June 19, 2023

Via The Motley Fool

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Via Investor's Business Daily

3 Innovative Growth Stocks to Buy for Next-Gen Profits ↗

May 31, 2023

Via InvestorPlace

RXDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Prometheus Biosciences, Inc. Is Fair to Shareholders

May 24, 2023

From Halper Sadeh LLC

Via Business Wire

PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX

May 22, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

3 Undervalued Pharma Stocks to Buy for High Total Returns ↗

May 19, 2023

Via InvestorPlace

FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A ↗

May 16, 2023

Via Benzinga

Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover ↗

May 16, 2023

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023 ↗

May 10, 2023

Via Benzinga

Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

May 09, 2023

From Prometheus Biosciences

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)

May 03, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)

May 01, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April ↗

April 30, 2023

Via Benzinga

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗

April 28, 2023

Via Investor's Business Daily

Merck Makes a Bold Move That Could Transform Its Business ↗

April 27, 2023

Via The Motley Fool

3 Biotechs That Might Get Bought Out in 2023 ↗

April 26, 2023

Via The Motley Fool

April 25, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

This Supercharged Dividend King Stock Might Soon Run Out of Steam ↗

April 25, 2023

Via The Motley Fool

PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX

April 21, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review ↗

April 21, 2023

Via Investor's Business Daily

Why Prometheus Biosciences Stock Is Skyrocketing This Week ↗

April 20, 2023

Via The Motley Fool

Why This Nasdaq Stock Caught Fire This Week ↗

April 20, 2023

Via The Motley Fool

Frequently Asked Questions

Is Prometheus Biosciences, Inc. - Common Stock publicly traded?

Yes, Prometheus Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Prometheus Biosciences, Inc. - Common Stock trade on?

Prometheus Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Prometheus Biosciences, Inc. - Common Stock?

The ticker symbol for Prometheus Biosciences, Inc. - Common Stock is RXDX on the Nasdaq Stock Market